NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Nectin-4 is the target for enfortumab vedotin, a novel antibody-drug conjugate. NECTIN4 gene expression differs considerably across different molecular subtypes and is shown to be important for enfortumab vedotin efficacy.See related article by Chu et al., p. 5123.

Keyphrases

gene expression
hodgkin lymphoma
cancer therapy
dna methylation
spinal cord injury
single cell
single molecule
young adults
drug induced
urinary tract